Test Summary

Meconium contains the amniotic fluid swallowed by the fetus in the last half of pregnancy and is released as the first stools after birth. Meconium is easier to collect than neonatal urine and provides a much longer window of exposure of up to 20 weeks. Meconium is an effective biological marker of in utero drug exposure, and can provide insights leading to improved neonatal outcomes, as well as provide evidence to ensure appropriate rehabilitation of mothers suffering from addiction. The test is a screening assay using a homogeneous enzyme immunoassay method of analysis. Presumptive positive screen results are reflexed to a more specific and sensitive mass spectroscopy (MS) methodology. Test results equal to or greater than cutoff are reported as positive and results less than cutoff are reported as negative. Quantitative values cannot be used to assess the amount of drug that the neonate was exposed.

Aliases

Specimen Collection

Special Instructions

Preferred Specimen

Minimum Volume

Instructions

Patient Preparation

Storage

Transport Temperature

Specimen Stability

Limitations

Other Acceptable Specimens

Unacceptable Specimens

Order Code

EPIC (Premier) Code

Includes

CPT Code

Billing Code

CPT Statement

Methodology

FDA Status

Physician Attestation of Informed Consent

Testing Laboratory

Department

Reference Range

Setup Schedule / Expected Turnaround Time